SG11201506479TA - Substituted xanthines and methods of use thereof - Google Patents

Substituted xanthines and methods of use thereof

Info

Publication number
SG11201506479TA
SG11201506479TA SG11201506479TA SG11201506479TA SG11201506479TA SG 11201506479T A SG11201506479T A SG 11201506479TA SG 11201506479T A SG11201506479T A SG 11201506479TA SG 11201506479T A SG11201506479T A SG 11201506479TA SG 11201506479T A SG11201506479T A SG 11201506479TA
Authority
SG
Singapore
Prior art keywords
methods
substituted xanthines
xanthines
substituted
Prior art date
Application number
SG11201506479TA
Inventor
Bertrand Chenard
Randall Gallaschun
Original Assignee
Hydra Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50680155&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201506479T(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hydra Biosciences Inc filed Critical Hydra Biosciences Inc
Publication of SG11201506479TA publication Critical patent/SG11201506479TA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Silver Salt Photography Or Processing Solution Therefor (AREA)
  • Medicinal Preparation (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
SG11201506479TA 2013-03-15 2014-03-14 Substituted xanthines and methods of use thereof SG11201506479TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361789724P 2013-03-15 2013-03-15
PCT/US2014/027920 WO2014143799A2 (en) 2013-03-15 2014-03-14 Substituted xanthines and methods of use thereof

Publications (1)

Publication Number Publication Date
SG11201506479TA true SG11201506479TA (en) 2015-09-29

Family

ID=50680155

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201506479TA SG11201506479TA (en) 2013-03-15 2014-03-14 Substituted xanthines and methods of use thereof

Country Status (32)

Country Link
US (6) US9359359B2 (en)
EP (1) EP2970303B3 (en)
JP (1) JP6360149B2 (en)
KR (1) KR102227629B1 (en)
CN (2) CN107082782B (en)
AU (1) AU2014228206C1 (en)
CA (1) CA2899646C (en)
CL (1) CL2015002738A1 (en)
CY (1) CY1119042T1 (en)
DK (1) DK2970303T6 (en)
EA (1) EA028815B1 (en)
ES (1) ES2636835T7 (en)
HK (1) HK1217329A1 (en)
HR (1) HRP20170840T4 (en)
HU (1) HUE033528T4 (en)
IL (1) IL240216B (en)
LT (1) LT2970303T (en)
MX (1) MX370372B (en)
MY (1) MY189912A (en)
NZ (1) NZ711718A (en)
PE (1) PE20151779A1 (en)
PH (1) PH12015502141A1 (en)
PL (1) PL2970303T6 (en)
PT (1) PT2970303T (en)
RS (1) RS56066B2 (en)
SG (1) SG11201506479TA (en)
SI (1) SI2970303T1 (en)
TW (1) TWI609867B (en)
UA (1) UA117470C2 (en)
UY (1) UY35488A (en)
WO (1) WO2014143799A2 (en)
ZA (1) ZA201505414B (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8173750B2 (en) 2009-04-23 2012-05-08 ATRP Solutions, Inc. Star macromolecules for personal and home care
AU2014228206C1 (en) 2013-03-15 2018-10-25 Hydra Biosciences, Llc Substituted xanthines and methods of use thereof
JP6667092B2 (en) * 2014-08-11 2020-03-18 ハイドラ・バイオサイエンシーズ・リミテッド・ライアビリティ・カンパニーHydra Biosciences, LLC Pyrrolo [3,2-d] pyrimidine-2,4 (3H, 5H) -dione derivative
WO2016159747A1 (en) 2015-03-27 2016-10-06 Latvian Institute Of Organic Synthesis Ethynylxanthines, preparation and use as calcium ion channel modulators
WO2016159746A1 (en) 2015-03-27 2016-10-06 Latvian Institute Of Organic Synthesis Novel ethynylxanthines, their preparation and use as inhibitors of matrix metalloproteinases and angiogenesis
CA2989161C (en) 2015-03-27 2022-03-01 Latvian Institute Of Organic Synthesis Ethynylxanthines, preparation and use for cancer treatment
BR112017021386A2 (en) * 2015-04-08 2018-07-03 Lewis And Clark Pharmaceuticals, Inc. substituted xanthine alkynyl carbamates / reverse carbamates as a2b antagonists.
CN107118586A (en) * 2016-02-24 2017-09-01 中国科学技术大学 The purposes of the vinyl compound of nitrogen heterocycle substitution
GB201702160D0 (en) * 2017-02-09 2017-03-29 Univ Leeds Innovations Ltd Inhibitors for use in therapy
WO2018157800A1 (en) * 2017-02-28 2018-09-07 National Institute Of Biological Sciences, Beijing Mlkl inhibitors
US11666577B2 (en) * 2017-02-28 2023-06-06 National Institute Of Biological Sciences, Beijing MLKL inhibitors
CN110997675B (en) * 2017-07-11 2022-06-07 勃林格殷格翰国际公司 Novel substituted xanthine derivatives
WO2019173327A1 (en) 2018-03-05 2019-09-12 Goldfinch Bio, Inc. Imidazodiazepinediones and methods of use thereof
DK3894410T3 (en) * 2018-12-12 2023-11-27 Boehringer Ingelheim Int SUBSTITUTED XANTHIND DERIVATIVES
JP7408662B2 (en) 2018-12-12 2024-01-05 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Substituted xanthan derivatives
CN112979651B (en) * 2021-04-09 2022-02-01 南京纽邦生物科技有限公司 Preparation method of hypoxanthine
CN113354646B (en) * 2021-07-06 2022-11-15 南开大学 8-aryloxy alkoxy substituted xanthine derivative and preparation method and application thereof
CN115636831A (en) * 2022-10-27 2023-01-24 中国药科大学 Fused pyrimidinediones, their use and pharmaceutical compositions

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4304650A1 (en) * 1993-02-16 1994-08-18 Thomae Gmbh Dr K Condensed 5-membered heterocycles, processes for their preparation and pharmaceutical compositions containing them
US6878715B1 (en) * 1994-02-18 2005-04-12 Cell Therapeutics, Inc. Therapeutic compounds for inhibiting interleukin-12 signals and method for using same
JP4191269B2 (en) 1996-05-17 2008-12-03 興和株式会社 Novel anilide compound and pharmaceutical containing the same
JPH10318487A (en) 1997-05-16 1998-12-04 Mitsubishi Gas Chem Co Inc Getter for vacuum insulating material
US6075029A (en) 1998-01-02 2000-06-13 Cell Therapeutics, Inc. Xanthine modulators of metabolism of cellular P-450
US6187780B1 (en) * 1998-04-16 2001-02-13 Boehringer Ingelheim Pharma Kg Assymetrically substituted xanthine derivatives having adenosine A1 antagonistic activity
MXPA01010143A (en) * 1999-04-09 2003-07-14 Cell Therapeutics Inc Xanthine derivatives and analogs as cell signaling inhibitors.
KR20030014394A (en) * 2000-07-04 2003-02-17 노보 노르디스크 에이/에스 Heterocyclic compounds, which are inhibitors of the enzyme dpp-iv
CN1486302A (en) 2000-12-07 2004-03-31 CV���ƹ�˾ Abca-1 elevating compounds against coronary artery disease or atherosclerosis
ES2282386T3 (en) * 2001-02-24 2007-10-16 BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG DERIVATIVES OF XANTINA, ITS PREPARATION AND ITS USE AS MEDICATIONS.
KR100937620B1 (en) * 2001-11-09 2010-01-20 씨브이 쎄러퓨틱스, 인코포레이티드 A2b adenosine receptor antagonists
ATE403656T1 (en) * 2003-05-06 2008-08-15 Cv Therapeutics Inc XANTHINE DERIVATIVES AS A2B ADENOSINE RECEPTOR ANTAGONISTS
EP1691891A2 (en) 2003-11-13 2006-08-23 The Board Of Regents, The University Of Texas System Inhibition of trp channels as a treatment for cardiac hypertrophy and heart failure
EP1841448A2 (en) 2004-12-30 2007-10-10 Diakine Therapeutics, Inc. Pharmaceutical compositions and methods for restoring beta-cell mass and function
WO2006089168A2 (en) 2005-02-18 2006-08-24 Cornell Research Foundation, Inc. Methods for modulating ion channels
TW200800217A (en) * 2005-08-10 2008-01-01 Smithkline Beecham Corp Novel compounds
DE602006012694D1 (en) 2005-09-06 2010-04-15 Glaxosmithkline Llc BENZIMIDAZOLTHIOPHONE COMPOUNDS AS PLK MODULATORS
JP2009518333A (en) * 2005-12-07 2009-05-07 ユセベ ファルマ ソシエテ アノニム Xanthine derivatives, methods for their preparation and uses thereof
CN101384261B (en) * 2005-12-22 2011-12-07 海德拉生物科学公司 Method and composition for treating pain
CA2637674A1 (en) 2006-01-19 2007-07-26 Abbott Laboratories 2-imino-benzimidazoles
WO2007101213A2 (en) 2006-02-28 2007-09-07 Kalypsys, Inc. Novel 2-oxo-1,2,3,4-tetrahydropyrimidines, bicyclic pyrimidine diones and imidazolidine-2,4-diones useful as inducible nitric oxide synthase inhibitors
WO2008011518A2 (en) 2006-07-19 2008-01-24 Diakine Therapeutics, Inc. Encapsulation system
WO2009157938A1 (en) * 2008-06-26 2009-12-30 Cv Therapeutics, Inc. A2b adenosine receptor antagonists for treating cancer
WO2011022638A1 (en) 2009-08-20 2011-02-24 Transposagen Biopharmaceuticals, Inc. Trp inhibitors and uses thereof
WO2011114184A1 (en) * 2010-03-15 2011-09-22 Glenmark Pharmaceuticals S.A. Amides of heterocyclic compounds as trpa1 inhibitors
WO2012050641A2 (en) 2010-06-08 2012-04-19 Hydra Biosciences, Inc Use of trpa1 antagonists to prevent or treat infections caused by biological-warfare agents
JP2013023102A (en) 2011-07-22 2013-02-04 Panasonic Corp Train information providing system
TW201311690A (en) * 2011-08-09 2013-03-16 Hydra Biosciences Inc Inhibiting transient receptor potential ion channel TRPA1
CN103121970B (en) 2012-12-04 2015-04-29 中国科学院昆明植物研究所 Benzimidazole and derivative thereof, and medicinal composition and application thereof in preparation of antidepressant medicaments
AU2014228206C1 (en) 2013-03-15 2018-10-25 Hydra Biosciences, Llc Substituted xanthines and methods of use thereof

Also Published As

Publication number Publication date
EA028815B1 (en) 2018-01-31
US20190322667A1 (en) 2019-10-24
UA117470C2 (en) 2018-08-10
TW201533044A (en) 2015-09-01
BR112015021164A8 (en) 2019-12-03
KR102227629B1 (en) 2021-03-16
JP2016513717A (en) 2016-05-16
AU2014228206A1 (en) 2015-09-24
MX2015011617A (en) 2016-04-25
EP2970303A2 (en) 2016-01-20
PH12015502141B1 (en) 2016-01-25
SI2970303T1 (en) 2017-08-31
CN107082782A (en) 2017-08-22
US10399982B2 (en) 2019-09-03
HK1217329A1 (en) 2017-01-06
HUE033528T4 (en) 2018-05-02
KR20150133233A (en) 2015-11-27
US20160237089A1 (en) 2016-08-18
ES2636835T7 (en) 2018-11-20
US9969736B2 (en) 2018-05-15
AU2014228206B2 (en) 2018-05-10
US20180244674A1 (en) 2018-08-30
PT2970303T (en) 2017-06-23
DK2970303T5 (en) 2018-01-02
TWI609867B (en) 2018-01-01
DK2970303T3 (en) 2017-06-26
MY189912A (en) 2022-03-21
AU2014228206C1 (en) 2018-10-25
RS56066B2 (en) 2018-09-28
ES2636835T3 (en) 2017-10-09
EA201591615A1 (en) 2016-05-31
EP2970303B3 (en) 2018-08-01
JP6360149B2 (en) 2018-07-18
US20170305910A1 (en) 2017-10-26
CY1119042T1 (en) 2018-01-10
RS56066B1 (en) 2017-10-31
CL2015002738A1 (en) 2016-06-10
CA2899646C (en) 2021-08-31
HUE033528T2 (en) 2017-12-28
LT2970303T (en) 2017-07-25
NZ711718A (en) 2020-05-29
PE20151779A1 (en) 2015-11-20
MX370372B (en) 2019-12-11
CA2899646A1 (en) 2014-09-18
PH12015502141A1 (en) 2016-01-25
PL2970303T3 (en) 2017-08-31
HRP20170840T4 (en) 2018-11-16
US11958854B2 (en) 2024-04-16
WO2014143799A3 (en) 2014-11-06
EP2970303B9 (en) 2017-09-20
IL240216B (en) 2018-11-29
CN105143229B (en) 2017-06-30
US20230040259A1 (en) 2023-02-09
WO2014143799A4 (en) 2015-02-12
BR112015021164A2 (en) 2017-07-18
WO2014143799A9 (en) 2014-12-24
US9359359B2 (en) 2016-06-07
CN107082782B (en) 2020-03-20
IL240216A0 (en) 2015-09-24
HRP20170840T1 (en) 2017-09-08
CN105143229A (en) 2015-12-09
ZA201505414B (en) 2016-03-30
PL2970303T6 (en) 2018-12-31
US11208409B2 (en) 2021-12-28
EP2970303B1 (en) 2017-05-10
WO2014143799A2 (en) 2014-09-18
UY35488A (en) 2014-10-31
US20140275071A1 (en) 2014-09-18
DK2970303T6 (en) 2018-10-08

Similar Documents

Publication Publication Date Title
HRP20170840T1 (en) Substituted xanthines and methods of use thereof
IL290547A (en) Antibodies and methods of use
IL244495A0 (en) Anti-alpha-synuclein antibodies and methods of use
GB2535360B (en) Methods of preparing polyhemiaminals and polyhexahydrotriazines
SG11201600707QA (en) Substituted aminopyrimidine compounds and methods of use
HK1225612A1 (en) Anti-ly6e antibodies and methods of use
HK1224307A1 (en) Protoxin-ii variants and methods of use -ii
HK1218247A1 (en) Probiotics and methods of use
IL245272A0 (en) Pif-transfected cells and methods of use